CD274 and neoplasm: TMIT I subgroup (PD-L1-positive tumor cells and CD8-high TILs) and TMIT III subgroup (PD-L1-positive tumor cells and CD8-low TILs) showed the best and worst outcomes of immunotherapy, respectively (73).